NCT05909553View on ClinicalTrials.gov

Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

September 22, 2023

Study Completion Date

September 22, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Venetoclax

Oral; Tablet

Trial Locations (1)

60030

Acpru /Id# 255783, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY

NCT05909553 - Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers | Biotech Hunter | Biotech Hunter